Review
Biochemistry & Molecular Biology
Gabriel Mendez-Valdes, Francisca Gomez-Hevia, Maria Chiara Bragato, Jose Lillo-Moya, Catalina Rojas-Sole, Luciano Saso, Ramon Rodrigo
Summary: Breast cancer is the most common malignant neoplastic disease in women, and its treatment depends on patient and tumor characteristics. The overexpression of the HER2 receptor, found in 15-25% of tumors, is associated with aggressive behavior and poor prognosis. Trastuzumab, a monoclonal antibody used as targeted therapy against HER2 receptor overexpression, has a major concern of cardiotoxicity. This review aims to explore the use of antioxidants as adjuvant therapy to prevent trastuzumab-induced cardiac toxicity and improve its safety profile.
Review
Medicine, Research & Experimental
Chunping Liu, Huiqi Chen, Sien Guo, Qiaojing Liu, Zhijun Chen, Haiding Huang, Qi Zhao, Longmei Li, Huan Cen, Zebo Jiang, Qiyuan Luo, Xiaoling Chen, Jiaxiong Zhao, Wensheng Chen, Phillip C. Yang, Lei Wang
Summary: With the progress of tumor treatment, the 5-year survival rate of breast cancer is close to 90%. Cardiovascular toxicity caused by chemotherapy has become a vital factor affecting the survival of patients with breast cancer. This article reviews the toxicity and mechanisms of current clinical anti-breast cancer drugs and proposes strategies for preventing cardiovascular toxicity.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Medicine, General & Internal
Sivisan Suntheralingam, Chun-Po Steve Fan, Oscar Calvillo-Arguelles, Husam Abdel-Qadir, Eitan Amir, Paaladinesh Thavendiranathan
Summary: This retrospective cohort study assessed the performance of three published risk prediction models in identifying the risk of Cancer-therapeutics-related cardiac dysfunction (CTRCD) during or immediately post treatment with trastuzumab therapy for HER2+ breast cancer. The results showed that these models can identify relative differences in CTRCD risk, but their ability to predict absolute risk is limited.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
Nathalie Bouwer, Tessa G. Steenbruggen, Hanah N. Rier, Jos J. E. M. Kitzen, Carolien H. Smorenburg, Marlies L. van Bekkum, Paul C. de Jong, Jan C. Drooger, Cynthia Holterhues, Marcel J. M. Kofflard, Eric Boersma, Gabe S. Sonke, Mark-David Levin, Agnes Jager
Summary: This study investigated the impact of trastuzumab on cardiac function in patients with HER2-positive metastatic breast cancer. The findings showed that despite having a reduced baseline left ventricular ejection fraction, 65% of patients did not develop severe cardiotoxicity during an 18-month follow-up. If severe cardiotoxicity did occur, it was partly reversible in more than two-thirds of the cases.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Cardiac & Cardiovascular Systems
Anthony F. Yu, Zachary R. Moore, Chaya S. Moskowitz, Jennifer E. Liu, Chau T. Dang, Lakshmi Ramanathan, Kevin C. Oeffinger, Richard M. Steingart, Adam M. Schmitt
Summary: This study found that higher cardiomyocyte cfDNA level after completion of anthracycline chemotherapy was associated with risk of CTRCD. Quantification of cardiomyocyte cfDNA holds promise as a predictive biomarker for risk stratification of CTRCD among patients with breast cancer receiving cardiotoxic cancer therapy and requires further validation.
Article
Oncology
N. Bouwer, T. G. Steenbruggen, J. van Rosmalen, H. N. Rier, J. J. E. M. Kitzen, M. L. van Bekkum, A. J. Ten Tije, P. C. de Jong, J. C. Drooger, C. Holterhues, C. H. Smorenburg, M. J. M. Kofflard, E. Boersma, G. S. Sonke, M-D Levin, A. Jager
Summary: According to the study, serial cardiac monitoring can be safely omitted in non-smoking patients with baseline LVEF > 60% and without cardiotoxicity during prior neoadjuvant/adjuvant treatment. The severity and reversibility of cardiotoxicity vary among patients receiving trastuzumab-based therapy.
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Review
Pharmacology & Pharmacy
Xinyi Li, Ziyang Wu, Xin Du, Yibo Wu, Xiaohui Xie, Luwen Shi
Summary: A systematic review revealed that reducing the duration of trastuzumab treatment can lower the risk of cardiotoxicity, while the use of cardioprotective drugs failed to effectively prevent trastuzumab-related cardiotoxic effects in breast cancer patients.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Oncology
Parvin F. Peddi, Peter A. Fasching, Duan Liu, Emmanuel Quinaux, Nicholas J. Robert, Vicente Valero, John Crown, Carla Falkson, Adam Brufsky, Julie M. Cunningham, Richard M. Weinshilboum, Tadeusz Pienkowski, Wolfgang Eiermann, Miguel Martin, Valerie Bee, Xiaoyan Wang, Liewei Wang, Eric Yang, Dennis J. Slamon, Sara A. Hurvitz
Summary: This study investigated the association between genetic polymorphisms and disease-free survival and cardiac toxicity in HER2-positive breast cancer patients treated with trastuzumab and/or anthracyclines. The results showed no correlation between the studied polymorphisms and disease-free survival or cardiac toxicity.
CLINICAL CANCER RESEARCH
(2022)
Review
Oncology
G. Nader-Marta, D. Martins-Branco, E. de Azambuja
Summary: HER2-positive breast cancer is a subtype of breast malignancy with aggressive behavior and high recurrence rates. The combination of trastuzumab, pertuzumab, and a taxane remains the preferred first-line therapy. Recent studies have shown that trastuzumab deruxtecan is more effective than trastuzumab emtansine as a second-line treatment. Other treatment options include T-DM1, tucatinib, trastuzumab, and capecitabine, as well as trastuzumab with different chemotherapy partners.
Article
Cardiac & Cardiovascular Systems
Wei-Ting Chang, Po-Wei Chen, Hui-Wen Lin, Sheng-Hsiang Lin, Yi-Heng Li
Summary: In a nationwide cohort study, it was found that there is an increased risk of major adverse cardiac and cerebrovascular events (MACCE), especially heart failure (HF), in breast cancer patients receiving trastuzumab treatment. The cardiotoxicity of trastuzumab may pose critical concerns for the cardiac safety of patients, independent of traditional cardiovascular risk factors.
Article
Cardiac & Cardiovascular Systems
Wei-Ting Chang, Po-Wei Chen, Hui-Wen Lin, Sheng-Hsiang Lin, Yi-Heng Li
Summary: In Taiwan, a higher incidence of MACCE, particularly heart failure (HF), was observed in breast cancer patients receiving trastuzumab. The cardiotoxicity of trastuzumab is independent of traditional cardiovascular risks, raising concerns about its cardiac safety. Subgroup analysis indicated increased risk of MACCE in trastuzumab users, especially those not using taxanes.
Article
Oncology
Lorenzo Livi, Giuseppe Barletta, Francesca Martella, Calogero Saieva, Isacco Desideri, Carlotta Bacci, Maria Riccarda Del Bene, Mario Airoldi, Domenico Amoroso, Luigi Coltelli, Vieri Scotti, Carlotta Becherini, Luca Visani, Viola Salvestrini, Matteo Mariotti, Fulvia Pedani, Marco Bernini, Luis Sanchez, Lorenzo Orzalesi, Jacopo Nori, Simonetta Bianchi, Iacopo Olivotto, Icro Meattini
Summary: The study aimed to evaluate whether pharmacological cardioprevention could reduce subclinical heart damage in breast cancer patients undergoing anthracycline-based chemotherapy. The results of the interim analysis suggested that cardioprotective pharmacological strategies were well tolerated and appeared to protect against cancer therapy-related left ventricular ejection fraction decline and heart remodeling.
Article
Oncology
Yan Lu, Aaron W. Gehr, Ifedioranma Anikpo, Rachel J. Meadows, Kevin J. Craten, Kalyani Narra, Anuradha Lingam, Sandeep Kamath, Bhavna Tanna, Bassam Ghabach, Rohit P. Ojha
Summary: This study aimed to estimate the cardiotoxicity risk among socioeconomically marginalized breast cancer patients treated with anthracyclines or trastuzumab and describe the clinical consequences of cardiotoxicity. The findings suggest a high risk of cardiotoxicity in this patient population after initiating anthracyclines or trastuzumab, with more than half of the patients experiencing treatment interruption.
BREAST CANCER RESEARCH AND TREATMENT
(2022)
Article
Medicine, General & Internal
Orianne de la Brassinne Bonardeaux, Benjamin Born, Marie Moonen, Patrizio Lancellotti
Summary: This retrospective study analyzed 23 patients who experienced decreased left ventricular function during trastuzumab treatment. Most patients showed mild, reversible myocardial dysfunction, and continuation of trastuzumab with close cardiac monitoring and cardioprotective measures could be considered. Initial left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS) levels appear to be reliable predictors of severe cardiotoxicity.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Oncology
Melanie Royce, Christy L. Osgood, Anup K. Amatya, Mallorie H. Fiero, C. J. George Chang, Tiffany K. Ricks, Krithika A. Shetty, Jeffrey Kraft, Junshan Qiu, Pengfei Song, Rosane Charlab, Jingyu Yu, Kathryn E. King, Anshu Rastogi, Brian Janelsins, Wendy C. Weinberg, Kathleen Clouse, Vicky Borders-Hemphill, Lindsey Brown, Candace Gomez-Broughton, Zhong Li, Thuy Thanh Nguyen, Zhihao Qiu, Anh-Thy Ly, Suyoung Chang, Tingting Gao, Chi-Ming Tu, Bellinda King-Kallimanis, William F. Pierce, Kelly Chiang, Clara Lee, Kirsten B. Goldberg, John K. Leighton, Shenghui Tang, Richard Pazdur, Julia A. Beaver, Laleh Amiri-Kordestani
Summary: Margetuximab-cmkb in combination with chemotherapy was granted regular FDA approval for the treatment of HER2-positive metastatic breast cancer patients who have received two or more prior anti-HER2 regimens. The SOPHIA study demonstrated that margetuximab had a longer median progression-free survival compared to trastuzumab when both were combined with chemotherapy. Infusion-related reactions were reported as important safety signals associated with margetuximab plus chemotherapy.
CLINICAL CANCER RESEARCH
(2022)
Article
Medicine, General & Internal
Omar Dewidar, Tamara Lotfi, Miranda W. Langendam, Elena Parmelli, Zuleika Saz Parkinson, Karla Solo, Derek K. Chu, Joseph L. Mathew, Elie A. Akl, Romina Brignardello-Petersen, Reem A. Mustafa, Lorenzo Moja, Alfonso Iorio, Yuan Chi, Carlos Canelo-Aybar, Tamara Kredo, Justine Karpusheff, Alexis F. Turgeon, Pablo Alonso-Coello, Wojtek Wiercioch, Annette Gerritsen, Miloslav Klugar, Maria Ximena Rojas, Peter Tugwell, Vivian Andrea Welch, Kevin Pottie, Zachary Munn, Robby Nieuwlaat, Nathan Ford, Adrienne Stevens, Joanne Khabsa, Zil Nasir, Grigorios Leontiadis, Joerg Meerpohl, Thomas Piggott, Amir Qaseem, Micayla Matthews, Holger J. Schunemann
Summary: An evidence-based approach is the gold standard for health decision-making, but the use of the GRADE approach for strong recommendations is inappropriate in cases where the evidence is indirect. We found widespread use of GPS in COVID-19 related recommendations, but guideline developers failed to transparently report their development process. We propose improvements to the operationalization of the GRADE guidance for GPS, including a structured process and standardized reporting.
BMJ EVIDENCE-BASED MEDICINE
(2023)
Article
Medicine, General & Internal
Carole Lunny, Areti Angeliki Veroniki, Brian Hutton, Ian White, Jpt Higgins, James M. Wright, Ji Yoon Kim, Sai Surabi Thirugnanasampanthar, Shazia Siddiqui, Jennifer Watt, Lorenzo Moja, Nichole Taske, Robert C. Lorenz, Savannah Gerrish, Sharon Straus, Virginia Minogue, Franklin Hu, Kevin Lin, Ayah Kapani, Samin Nagi, Lillian Chen, Mona Akbar-nejad, Andrea C. Tricco
Summary: This study aimed to develop a risk of bias (RoB) tool for assessing network meta-analysis (NMA) and gather opinions from knowledge users. The Delphi process and knowledge user survey identified the content of the RoB NMA tool and revealed a preference for assessing both individual NMA results and authors' conclusions.
BMJ EVIDENCE-BASED MEDICINE
(2023)
Article
Nutrition & Dietetics
Giovanna Esposito, Federica Turati, Diego Serraino, Anna Crispo, Eva Negri, Fabio Parazzini, Carlo La Vecchia
Summary: Adherence to the recommendations of the WCRF/AICR has a favorable role in reducing endometrial cancer risk, particularly among women with normal weight, older age, post-menopause, and those with more than 2 children.
BRITISH JOURNAL OF NUTRITION
(2023)
Article
Nutrition & Dietetics
Federica Turati, Federica Concina, Marta Rossi, Federica Fiori, Maria Parpinel, Martina Taborelli, Attilio Giacosa, Anna Crispo, Eleonora Pagan, Valentina Rosato, Eva Negri, Carlo La Vecchia
Summary: This study found an inverse association between the intake of galactooligosaccharides (GOSs) and colorectal cancer risk. No association was found with total inulin-type fructans (ITFs) and fructooligosaccharides (FOSs).
EUROPEAN JOURNAL OF NUTRITION
(2023)
Review
Public, Environmental & Occupational Health
Periklis Charalampous, Juanita A. Haagsma, Lea S. Jakobsen, Vanessa Gorasso, Isabel Noguer, Alicia Padron-Monedero, Rodrigo Sarmiento, Joao Vasco Santos, Scott A. McDonald, Dietrich Plass, Grant M. A. Wyper, Ricardo Assuncao, Elena von der Lippe, Balazs Adam, Ala'a AlKerwi, Jalal Arabloo, Ana Lucia Baltazar, Boris Bikbov, Maria Borrell-Pages, Iris Brus, Genc Burazeri, Serafeim C. Chaintoutis, Jose Chen-Xu, Nino Chkhaberidze, Seila Cilovic-Lagarija, Barbara Corso, Sarah Cuschieri, Carlotta Di Bari, Keren Dopelt, Mary Economou, Theophilus Emeto, Peter Fantke, Florian Fischer, Alberto Freitas, Juan Manuel Garcia-Gonzalez, Federica Gazzelloni, Mika Gissler, Artemis Gkitakou, Hakan Gulmez, Sezgin Gunes, Sebastian Haller, Romana Haneef, Cesar A. Hincapie, Paul Hynds, Jane Idavain, Milena Ilic, Irena Ilic, Gaetano Isola, Zubair Kabir, Maria Kamusheva, Pavel Kolkhir, Naime Meric Konar, Polychronis Kostoulas, Mukhtar Kulimbet, Carlo La Vecchia, Paolo Lauriola, Miriam Levi, Marjeta Majer, Enkeleint A. Mechili, Lorenzo Monasta, Stefania Mondello, Javier Munoz Laguna, Evangelia Nena, Edmond S. W. Ng, Paul Nguewa, Vikram Niranjan, Iskra Alexandra Nola, Ronan O'Caoimh, Marija Obradovic, Elena Pallari, Mariana Peyroteo, Vera Pinheiro, Nurka Pranjic, Miguel Reina Ortiz, Silvia Riva, Cornelia Melinda Adi Santoso, Milena Santric Milicevic, Tugce Schmitt, Niko Speybroeck, Maximilian Sprugel, Paschalis Steiropoulos, Aleksandar Stevanovic, Lau Caspar Thygesen, Fimka Tozija, Brigid Unim, Hilal Bektas Uysal, Orsolya Varga, Milena Vasic, Rafael Jose Vieira, Vahit Yigit, Brecht Devleesschauwer, Sara M. Pires
Summary: This systematic literature review provides an overview of studies applying the disability-adjusted life years (DALY) concept for infectious diseases in European countries. Among the 105 included studies, food- and water-borne diseases were the most frequently studied. The number of burden of infectious disease studies has increased over time, but there is less consensus in methodological approaches.
EPIDEMIOLOGY AND INFECTION
(2023)
Article
Oncology
Giulia Collatuzzo, Carlo La Vecchia, Fabio Parazzini, Gianfranco Alicandro, Federica Turati, Matteo Di Maso, Matteo Malvezzi, Claudio Pelucchi, Eva Negri, Paolo Boffetta
Summary: This study provides a comprehensive assessment of infection-related cancers burden in Italy. It shows that 7.6% of cancer deaths and 6.9% of incident cases are attributable to infections, with higher proportions in men than women. Helicobacter pylori is the leading cause of infection-related cancer deaths, followed by hepatitis C virus, human immunodeficiency virus, and hepatitis B virus.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Barbara D'Avanzo, Ilaria Ardoino, Eva Negri, Diego Serraino, Anna Crispo, Attilio Giacosa, Werner Garavello, Francesca Bravi, Federica Turati, Cristina Bosetti, Elena Fattore, Carlo La Vecchia, Carlotta Franchi
Summary: This study investigated the relationship between canned fish consumption and the risk of upper digestive tract cancers. The findings suggest that canned fish may have a beneficial role in reducing the risk of oral cavity and pharynx cancer and gastric cancer, but not esophageal cancer.
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL
(2023)
Review
Oncology
Flavia Jacobs, Mariangela Gaudio, Chiara Benvenuti, Rita De Sanctis, Armando Santoro, Alberto Zambelli
Summary: Great progress has been made in personalized treatment for breast cancer oncology, with the introduction of genomic signature testing being particularly important. The aim of this review is to discuss the challenges and urgent issues related to its daily use, providing insights for better integration and wider application in clinical practice. The review focuses on the integration of genomic data with clinicopathological factors, the potential clinical impact of genomic testing in different patient populations and settings, and the optimization of test ordering.
Review
Oncology
Antonio Cioffi, Ottavio De Cobelli, Paolo Veronesi, Carlo La Vecchia, Patrick Maisonneuve, Giovanni Corso
Summary: This systematic review and meta-analysis found that germline BRCA1 variants are more prevalent in Ashkenazi Jewish men with prostate cancer, while BRCA2 variants show a similar distribution between Ashkenazi and non-Ashkenazi populations. This suggests that genetic screening for prostate cancer in Ashkenazi men should not be limited to the BRCA2 gene.
Article
Oncology
M. Malvezzi, C. Santucci, P. Boffetta, G. Collatuzzo, F. Levi, C. La Vecchia, E. Negri
Summary: This study predicts cancer mortality figures for 2023 in the European Union, its five most populous countries, and the UK, with a focus on lung cancer. The results show that the decline in lung cancer mortality reflects advancements in tobacco control, and further efforts are needed to control overweight and obesity, alcohol consumption, infection, and related neoplasms, as well as improve screening, early diagnosis, and treatments. These efforts may achieve a 35% reduction in cancer mortality in the EU by 2035.
ANNALS OF ONCOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Simona Servida, Elena Panzeri, Laura Tomaino, Giovanni Marfia, Emanuele Garzia, Giuseppe Ciniglio Appiani, Gianluca Moroncini, Vito De Gennaro Colonna, Carlo La Vecchia, Luisella Vigna
Summary: This article discusses a case study of a helicopter pilot who experienced transient loss of consciousness during a low-altitude flight under curcumin and piperine treatment. Further investigation revealed the presence of previously asymptomatic insulinoma. The researchers hypothesize that the combined effects of curcumin and piperine may have caused severe hypoglycemia and subsequent loss of consciousness. Thus, more studies are needed to evaluate the safety of curcumin and piperine supplementation in individuals with impaired glucose metabolism and insulin secretion.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Giulia Collatuzzo, Claudia Santucci, Matteo Malvezzi, Carlo La Vecchia, Paolo Boffetta, Eva Negri
Summary: This study found that gastric cancer mortality rates have been declining globally since 1990, with variations between countries and regions. It is predicted that gastric cancer mortality rates will continue to decline in most countries, except for certain demographics in France, the US, and Canada. The proportion of cardia and noncardia gastric cancer also varies across different regions.
Review
Biochemistry & Molecular Biology
Paola Tiberio, Alessandro Vigano, Mariya Boyanova Ilieva, Sebastiano Pindilli, Anna Bianchi, Alberto Zambelli, Armando Santoro, Rita De Sanctis
Summary: Numerous epidemiological studies have explored the potential link between migraine and breast cancer due to their association with female reproductive hormones. Current evidence suggests a protective role of migraine in breast cancer development, particularly in case-control studies. However, the inconsistency among studies and recent research challenging this concept indicate a more complex relationship between the two conditions. Further studies are needed to validate the protective role of migraine in breast cancer and identify the precise nature of this causal relationship.
Review
Biochemistry & Molecular Biology
Chiara Benvenuti, Mariangela Gaudio, Flavia Jacobs, Giuseppe Saltalamacchia, Rita De Sanctis, Rosalba Torrisi, Armando Santoro, Alberto Zambelli
Summary: Visceral crisis is a life-threatening condition in advanced breast cancer, but its clinical definition is unclear, making it challenging to manage. Chemotherapy is recommended as first-line treatment, but its effectiveness is limited and the prognosis is poor. The available evidence is mainly from retrospective studies, and the role of chemotherapy is questioned with the introduction of innovative drugs. This article aims to critically discuss the management of visceral crisis and explore future treatment perspectives.
Article
Medical Laboratory Technology
Ali Esmaeili-Nadimi, Fatemeh Imanparast, Samira Alizadeh, Akram Vatannejad, Pegah Mohaghegh, Seyed M. Seyedmehdi, Carlo La Vecchia, Zahra Jamali
Summary: This study investigated the relationship between total antioxidant capacity (TAC), total oxidant status (TOS), TAC/TOS levels, and disease severity in hospitalized patients with COVID-19. The results showed no significant difference in serum levels of TAC, TOS, and TAC/TOS in terms of disease severity.
CLINICAL LABORATORY
(2023)
Article
Oncology
Diego de Miguel-Perez, Edward M. Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A. Pinto, Alessandro Russo, Giancarlo Troncone, Melissa J. Culligan, Katherine A. Scilla, Ranee Mehra, Pranshu Mohindra, Oscar Arrieta, Andres F. Cardona, Marzia Del Re, Ashutosh Sachdeva, Fred R. Hirsch, Andrea Wolf, Joseph S. Friedberg, Christian Rolfo
Summary: In this study, genetic alterations in resectable pleural mesothelioma tissues and blood samples were analyzed, and it was found that high tissue tumor mutational burden, tissue median minor allele frequency, blood tumor mutational burden, and specific mutations were correlated with outcomes in patients with resected PM. These findings suggest that molecular profiling could help identify longer survivors in patients with resected PM.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Davide Melisi, Camilla Zecchetto, Valeria Merz, Giuseppe Malleo, Luca Landoni, Alberto Quinzii, Simona Casalino, Federica Fazzini, Marina Gaule, Camilla Pesoni, Luca Casetti, Alessandro Esposito, Giovanni Marchegiani, Cristiana Piazzola, Mirko D'Onofrio, Riccardo de Robertis, Armando Gabbrielli, Laura Bernardoni, Stefano F. Crino, Silvia Pietrobono, Claudio Luchini, Camillo Aliberti, Guido Martignoni, Stefano Milleri, Giovanni Butturini, Aldo Scarpa, Roberto Salvia, Claudio Bassi
Summary: This study evaluated the safety and activity of liposomal irinotecan in the perioperative treatment of resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that NALIRIFOX has manageable and active outcomes, and should be further investigated in randomized trials comparing it to standard upfront surgery followed by adjuvant therapy.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. Mcdermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri
Summary: After a median follow-up of 41.2 months, belzutifan monotherapy demonstrated durable antitumor activity in patients with advanced ccRCC and acceptable safety.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Patricia A. H. Hamers, Geraldine R. Vink, Marloes A. G. Elferink, Leon M. G. Moons, Cornelis J. A. Punt, Anne M. May, Miriam Koopman
Summary: Screen-detection of the primary tumor is associated with longer overall survival after metachronous metastasis.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Camilla Nero, Nicolo Bizzarri, Stefano Di Berardino, Francesca Sillano, Giuseppe Vizzielli, Francesco Cosentino, Virginia Vargiu, Pierandrea De Iaco, Anna Myriam Perrone, Enrico Vizza, Benito Chiofalo, Stefano Uccella, Fabio Ghezzi, Luigi Carlo Turco, Giacomo Corrado, Diana Giannarelli, Tina Pasciuto, Gian Franco Zannoni, Anna Fagotti, Giovanni Scambia
Summary: This study evaluates the sensitivity and specificity of sentinel-lymph-node mapping compared to systematic lymphadenectomy in detecting lymph node metastasis in early stage ovarian cancer. The results show that sentinel-lymph-node mapping did not reach the expected sensitivity, but ultra-staging protocol improved the accuracy of diagnosis for patients.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies
Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina Kuna, Cathy J. Bradley, Lavanya Kondapalli, Jennifer R. Diamond
Summary: This study evaluates major adverse cardiovascular events (MACE) in older women with TNBC treated with anthracycline and taxane-based chemotherapy (ATAX) compared to taxane-based chemotherapy (TAX). The results show that ATAX does not increase the risk of MACE and there is no difference in survival between patients who received TAX and ATAX.
EUROPEAN JOURNAL OF CANCER
(2024)
Letter
Oncology
Pei-Chun Weng, Yau-Li Huang, Chun-Yu Cheng
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank
Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Casper W. F. van Eijck, Gaby Strijk, Eveline E. Vietscha, Fleur van der Sijde, Maaike Verheij, Dana A. M. Mustafa, Madelief Vinkc, Joachim G. J. V. Aerts, Casper H. J. van Eijck, Marcella Willemsen
Summary: The study reveals that FOLFIRINOX has immunomodulatory effects, suggesting its potential in immune-based combination therapies for pancreatic cancer. Additionally, certain plasma proteins hold promise as circulating predictive biomarkers for early prediction of FOLFIRINOX response in patients with pancreatic cancer.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Marwan Fakih, Chongkai Wang, Jaideep Sandhu, Jian Ye, Colt Egelston, Xiaochen Li
Summary: This study explores the impact of metastatic sites on treatment outcomes for chemotherapy-refractory colorectal cancer patients. It found that patients with liver or peritoneal metastases had poor treatment outcomes, while those with lung-only metastases showed significant response. The presence of concurrent lymph node or other extrahepatic metastatic disease diminished treatment response in patients with lung metastases. Future checkpoint inhibitor trials should stratify patients based on metastatic locations.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Georgios Christos Tsiatsianis, Candace S. Y. Chan, Ioannis Mouratidis, Nikol Chantzi, Anna Maria Tsiatsiani, Nelson S. Yee, Apostolos Zaravinos, Verena Kantere, Ilias Georgakopoulos-Soares
Summary: The study reveals that nullpeptides can serve as biomarkers for cancer detection and treatment, particularly in highly recurrent cancer patients. These nullpeptides primarily occur in highly expressed genes, particularly in specific loci of oncogenes and tumor suppressors. Recurrent nullpeptides are more likely to be found in neoantigens, which play a significant role in immunotherapy.
EUROPEAN JOURNAL OF CANCER
(2024)